2020
Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas
Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationMF/SSTime of transplantStem cell transplantationT-cell lymphomaMedian followCell transplantationCell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaGamma-delta T-cell lymphomaMF/SS patientsLong-term complete responseCutaneous T-cell lymphomaTotal skin electron beamRefractory mycosis fungoidesClinical complete remissionDisease-free survivalComplete remissionOverall survivalPartial responseSkin involvementComplete responseMycosis fungoidesSS patients
2019
Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience
Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda L, Foss F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience. Transplantation And Cellular Therapy 2019, 25: s387. DOI: 10.1016/j.bbmt.2018.12.796.Peer-Reviewed Original ResearchT-cell lymphomaProgression-free survivalTransplant related mortalityCumulative incidenceOverall survivalAutologous stem cell transplant consolidationOne-year progression-free survivalT-cell-rich B-cellT-cell lymphoma typesCutaneous T-cell lymphomaLong-term prospective studiesT-cell lymphoma subtypesPost-transplant relapseReduced intensity regimensTBI/CYHigh-dose chemotherapyNK T cellsSingle-center experienceOverall favorable outcomeKaplan-Meier analysisPretransplant conditioning regimenAllogeneic stem cellsPeripheral T-cell lymphoma subtypesAutologous SCTChronic GVHD
2013
A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients
Fraser J, Lansigan F, Seropian S, Barbarotta L, Foss F. A Pilot Study Of Sorafenib In Refractory Or Relapsed T-Cell Lymphoma Patients. Blood 2013, 122: 4356. DOI: 10.1182/blood.v122.21.4356.4356.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaRefractory T-cell lymphomaStarting doseStage IIBSkin toxicityPilot studyClinical activityRelapsed T-cell lymphomaAllogeneic stem cell transplantAngioimmunoblastic T-cell lymphomaT-cell lymphoma patientsPlatelet-derived growth factor receptor alphaProgression-free survivalStem cell transplantDuration of responseGrowth factor receptor alphaOff-label useT-cell NHLNumber of therapiesMulti-kinase inhibitorAdvisory CommitteeClinical CRStable disease
2008
A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience
Lansigan F, Seropian S, Cooper D, Foss F. A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience. Blood 2008, 112: 4392. DOI: 10.1182/blood.v112.11.4392.4392.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaAngioimmunoblastic T-cell lymphomaT-cell lymphomaAlloSCT groupNon-Hodgkin lymphomaFirst remissionComplete remissionPartial remissionDonor transplantsAggressive peripheral T-cell lymphomaRefractory cutaneous T-cell lymphomaSurvival rateMatched-unrelated donor transplantProgression-free survival ratesTransplant-related mortality rateAllogeneic stem cell transplantationHepatosplenic T-cell lymphomaPanniculitic T-cell lymphomaAnaplastic large cell lymphomaFirst complete remissionNon-relapse mortalityReduced-intensity transplantsSecond complete remissionOverall survival rate